Potentiation of natural killer cells to overcome cancer resistance to NK cell-based therapy and to enhance antibody-based immunotherapy

被引:9
作者
Fantini, Massimo [1 ]
Arlen, Philip Martin [1 ]
Tsang, Kwong Yok [1 ]
机构
[1] Precis Biol Inc, Bethesda, MD 20814 USA
来源
FRONTIERS IN IMMUNOLOGY | 2023年 / 14卷
关键词
NK cells; ADCC; modulatory cytokines; adoptive NK cell therapy; monoclonal antibody; CAR-NK; LONG-TERM SAFETY; METASTATIC UROTHELIAL CARCINOMA; GAMMA-RIIIA POLYMORPHISMS; C-RECEPTOR POLYMORPHISMS; PHASE-I; COLORECTAL-CANCER; CORD BLOOD; MEDIATED CYTOTOXICITY; IMMUNE-SYSTEM; SOLUBLE MICA;
D O I
10.3389/fimmu.2023.1275904
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Natural killer (NK) cells are cellular components of the innate immune system that can recognize and suppress the proliferation of cancer cells. NK cells can eliminate cancer cells through direct lysis, by secreting perforin and granzymes, or through antibody-dependent cell-mediated cytotoxicity (ADCC). ADCC involves the binding of the Fc gamma receptor IIIa (CD16), present on NK cells, to the constant region of an antibody already bound to cancer cells. Cancer cells use several mechanisms to evade antitumor activity of NK cells, including the accumulation of inhibitory cytokines, recruitment and expansion of immune suppressor cells such as myeloid-derived suppressor cells (MDSCs) and regulatory T cells (Tregs), modulation of ligands for NK cells receptors. Several strategies have been developed to enhance the antitumor activity of NK cells with the goal of overcoming cancer cells resistance to NK cells. The three main strategies to engineer and boost NK cells cytotoxicity include boosting NK cells with modulatory cytokines, adoptive NK cell therapy, and the employment of engineered NK cells to enhance antibody-based immunotherapy. Although the first two strategies improved the efficacy of NK cell-based therapy, there are still some limitations, including immune-related adverse events, induction of immune-suppressive cells and further cancer resistance to NK cell killing. One strategy to overcome these issues is the combination of monoclonal antibodies (mAbs) that mediate ADCC and engineered NK cells with potentiated anti-cancer activity. The advantage of using mAbs with ADCC activity is that they can activate NK cells, but also favor the accumulation of immune effector cells to the tumor microenvironment (TME). Several clinical trials reported that combining engineered NK cells with mAbs with ADCC activity can result in a superior clinical response compared to mAbs alone. Next generation of clinical trials, employing engineered NK cells with mAbs with higher affinity for CD16 expressed on NK cells, will provide more effective and higher-quality treatments to cancer patients.
引用
收藏
页数:20
相关论文
共 50 条
[21]   Antibody-based therapy in colorectal cancer [J].
Noguchi, Takuro ;
Ritter, Gerd ;
Nishikawa, Hiroyoshi .
IMMUNOTHERAPY, 2013, 5 (05) :533-545
[22]   Natural killer cell-based immunotherapy: From transplantation toward targeting cancer stem cells [J].
Dianat-Moghadam, Hassan ;
Rokni, Mohsen ;
Marofi, Faroogh ;
Panahi, Yunes ;
Yousefi, Mehdi .
JOURNAL OF CELLULAR PHYSIOLOGY, 2019, 234 (01) :259-273
[23]   Potentiation of Natural Killer Cells for Cancer Immunotherapy: A Review of Literature [J].
Lowry, Lacy E. ;
Zehring, William A. .
FRONTIERS IN IMMUNOLOGY, 2017, 8
[24]   Natural killer cell-based cancer immunotherapy: from basics to clinical trials [J].
Shi, Yinghong ;
Hao, Donglin ;
Qian, Hui ;
Tao, Zhimin .
EXPERIMENTAL HEMATOLOGY & ONCOLOGY, 2024, 13 (01)
[25]   Natural killer (NK) cell-based immunotherapies and the many faces of NK cell memory: A look into how nanoparticles enhance NK cell activity [J].
Mikelez-Alonso, Idoia ;
Magadan, Susana ;
Gonzalez-Fernandez, Africa ;
Borrego, Francisco .
ADVANCED DRUG DELIVERY REVIEWS, 2021, 176 (176)
[26]   Neutrophils as effector cells for antibody-based immunotherapy of cancer [J].
van Egmond, Marjolein ;
Bakema, Jantine E. .
SEMINARS IN CANCER BIOLOGY, 2013, 23 (03) :190-199
[27]   Natural Killer Cell-Based Immunotherapy in Gynecologic Malignancy: A Review [J].
Uppendahl, Locke D. ;
Dahl, Carly M. ;
Miller, Jeffrey S. ;
Felices, Martin ;
Geller, Melissa A. .
FRONTIERS IN IMMUNOLOGY, 2018, 8
[28]   Design and Implementation of NK Cell-Based Immunotherapy to Overcome the Solid Tumor Microenvironment [J].
Navin, Ishwar ;
Lam, Michael T. ;
Parihar, Robin .
CANCERS, 2020, 12 (12) :1-22
[29]   Current progress in NK cell biology and NK cell-based cancer immunotherapy [J].
Raquel Tarazona ;
Nelson Lopez-Sejas ;
Beatriz Guerrero ;
Fakhri Hassouneh ;
Isabel Valhondo ;
Alejandra Pera ;
Beatriz Sanchez-Correa ;
Nieves Pastor ;
Esther Duran ;
Corona Alonso ;
Rafael Solana .
Cancer Immunology, Immunotherapy, 2020, 69 :879-899
[30]   NK Cell-Based Immunotherapy in Renal Cell Carcinoma [J].
Terren, Inigo ;
Orrantia, Ane ;
Mikelez-Alonso, Idoia ;
Vitalle, Joana ;
Zenarruzabeitia, Olatz ;
Borrego, Francisco .
CANCERS, 2020, 12 (02)